STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #809 by analyst upside · 2026-09-09
EPRX
Eupraxia Pharmaceuticals Inc.
Healthcare · Market Cap $545M · P/E 0x
ANALYST PRICE TARGET
+98.2%
implied upside to consensus target
Current Price $8.25
Consensus Target $16.35
Bull Target $25.0
Bear Target $11.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
10
Hold
0
Sell
0
52-Week Low $5.16
52-Week High $9.32
YTD Return +9.0%
FUNDAMENTALS
Market Cap $545M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.02
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $5.16
52-Week High $9.32
Current Price $8.25
Bear Target $11.0
Bull Target $25.0
● Now $8.25 ● Target $16.35
TRADING DATA
Avg Volume 431K
YTD Return +9.0%
Analyst Count 10
Consensus Buy
Upside to Target +98.2%
Last Updated 2026-09-09

ANALYST SUMMARY

Eupraxia Pharmaceuticals Inc. (EPRX) is currently trading at $8.25 with a Wall Street consensus price target of $16.35, implying potential upside of 98.2% over the next 12 months. 10 analysts currently cover EPRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $25.0, while the most cautious has a target of $11.0.

EPRX operates in the Healthcare sector with a market capitalisation of $545M. The stock is up 9.0% year-to-date and is currently trading near the upper end of its 52-week range of $5.16 – $9.32.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for EPRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer ● Initiated
Outperform 2026-06-26 14% win rate (7 calls)
Stifel ● Initiated
Buy 2026-05-21 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-05-04 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-04-22 31% win rate (48 calls)
William Blair ● Initiated
Outperform 2026-03-23 44% win rate (9 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-17 31% win rate (48 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-01-15 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →